Clinical trials
Disease trials in Taiwan
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
36 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Unknown status | 11 |
| Recruiting | 9 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Taiwan University Hospital | 9 |
| Chang Gung Memorial Hospital | 5 |
| Kaohsiung Medical University Chung-Ho Memorial Hospital | 2 |
| Taichung Veterans General Hospital | 2 |
| Taipei Medical University | 2 |
| Tri-Service General Hospital (TSGH) | 2 |
| Wang . Jiun-Jie | 2 |
| Academia Sinica, Taiwan | 1 |
| Anbogen Therapeutics, Inc. | 1 |
| AstraZeneca | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease | 36 |
| Lung Neoplasms | 5 |
| Parkinson Disease | 3 |
| Alzheimer Disease | 2 |
| Cognitive Dysfunction | 2 |
| Colorectal Neoplasms | 2 |
| Schizophrenia | 2 |
| Anxiety Disorders | 1 |
| Asthma | 1 |
| Asymptomatic Diseases | 1 |
Trials
Showing 1 to 25 of 36. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.